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Abstract 
Acute and chronic inflammatory diseases of the intestine impart a significant and negative impact on the health and 
well-being of human and non-human mammalian animals. Understanding the underlying mechanisms of inflam-
matory disease is mandatory to develop effective treatment and prevention strategies. As inflammatory disease 
etiologies are multifactorial, the use of appropriate animal models and associated metrics of disease are essential. 
In this regard, animal models used alone or in combination to study acute and chronic inflammatory disease of the 
mammalian intestine paired with commonly used inflammation-inducing agents are reviewed. This includes both 
chemical and biological incitants of inflammation, and both non-mammalian (i.e. nematodes, insects, and fish) and 
mammalian (i.e. rodents, rabbits, pigs, ruminants, dogs, and non-human primates) models of intestinal inflammation 
including germ-free, gnotobiotic, as well as surgical, and genetically modified animals. Importantly, chemical and 
biological incitants induce inflammation via a multitude of mechanisms, and intestinal inflammation and injury can 
vary greatly according to the incitant and animal model used, allowing studies to ascertain both long-term and short-
term effects of inflammation. Thus, researchers and clinicians should be aware of the relative strengths and limitations 
of the various animal models used to study acute and chronic inflammatory diseases of the mammalian intestine, 
and the scope and relevance of outcomes achievable based on this knowledge. The ability to induce inflammation to 
mimic common human diseases is an important factor of a successful animal model, however other mechanisms of 
disease such as the amount of infective agent to induce disease, invasion mechanisms, and the effect various physi-
ologic changes can have on inducing damage are also important features. In many cases, the use of multiple animal 
models in combination with both chemical and biological incitants is necessary to answer the specific question being 
addressed regarding intestinal disease. Some incitants can induce acute responses in certain animal models while 
others can be used to induce chronic responses; this review aims to illustrate the strengths and weaknesses in each 
animal model and to guide the choice of an appropriate acute or chronic incitant to facilitate intestinal disease.
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Background
Diseases are often categorized by the organs affected and 
the resulting clinical manifestations produced. Inflamma-
tion is a collection of conserved immunological processes 
that lead to the recovery and repair of damaged tis-
sue, with the potential to cause more damage and harm 
when insufficiently regulated. In the intestine, controlled 
inflammation is necessary for immunological function, 
as regulatory immune cells are continually interacting 
with intestinal bacteria and food particles to regulate 
pro-inflammatory effector cells and facilitate anti-inflam-
matory pathways [1]. Events such as epithelial barrier 
disruptions, uncontrolled bacterial colonization, unregu-
lated immune effector cell stimulation and the dysregula-
tion of the homeostatic balance can contribute to disease 
onset. Furthermore, these events can manifest anywhere 
in the small intestine (i.e. duodenum, jejunum, ileum) 
and/or large intestine (i.e. cecum, appendix, colon, rec-
tum) [2, 3]. Disease duration is also an important factor 
in characterizing intestinal disease with chronic diseases 
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persisting for months or longer, and acute diseases last-
ing only weeks, typically from 7 to 14 days [4, 5].
Acute and chronic inflammatory diseases of the intes-
tine induce a number of health-related problems, and 
decrease the quality of life in people in both develop-
ing and developed countries [6, 7]. Diarrhea is a com-
mon presentation of intestinal enteritis, and nearly 1.7 
billion cases of diarrheal disease are reported glob-
ally each year [8], however cases of enteritis often go 
unreported due to their self-limiting nature [9]. In 
North America and Australia, the prevalence of acute 
enteritis incited by foodborne pathogens alone is esti-
mated to affect approximately 10–20  % of the human 
population annually [9]. Importantly, acute enteritis or 
diarrheal disease is the second leading cause of death 
worldwide, accounting for over 1 million deaths annu-
ally [10] with higher mortality rates in developing coun-
tries [11]. Acute enteritis also imparts significant direct 
and indirect costs to society, including lost worker pro-
ductivity and direct impacts on health care systems. In 
Canada for example, intestinal disease is responsible for 
the hospitalization of 4  % of children ≤5  years of age 
[12]. In the United States, the Center for Disease Con-
trol reported that costs for hospitalization, emergency 
room visits and outpatient care for children with viral-
induced acute enteritis averaged $273 million from 2009 
to 2010 [13], while in Canada in recent years, acute 
enteritis incited by viruses was estimated at $20 mil-
lion dollars in hospitalization costs for older individuals 
[14]. Large numbers of people also suffer from chronic 
inflammatory diseases of the intestine, and chronic 
enteritis rates continue to rise [15, 16]. Inflammatory 
bowel disease (IBD) is the most important chronic 
inflammatory disease of people, and it includes Crohn’s 
disease (CD) and ulcerative colitis (UC) [16]. In Can-
ada approximately 0.7  % of the population were living 
with inflammatory bowel disease in 2012 [17, 18], and 
diagnosis and treatment costs to the health care system 
for Canadians afflicted with CD or UC was estimated 
at $1.2 billion [18]. Other developed nations such as 
Europe and Australia also have a high prevalence of IBD 
[19, 20], and rates in Asian countries are increasing [15]. 
Chronic inflammatory diseases of the intestine have 
a tremendous negative impact on the health and well-
being of individuals and costs to health care systems.
Although inflammatory diseases of the intestine are 
often referenced with regard to their localized and tem-
poral inflammatory effects within the small or large intes-
tine, uncontrolled inflammation of the intestine always 
imparts a systemic impact on the body [21, 22] (Fig. 1). 
Significantly, the etiology of both acute and chronic intes-
tinal inflammatory disease is often enigmatic, [16, 23] 
thereby compromising treatment choices and efficacy. 
Furthermore, chronic inflammatory diseases of the intes-
tine such as IBD are often linked to prior acute inflam-
matory disease incited by viruses, bacteria, parasites 
[24], dysregulation of the intestinal immune response, or 
autoimmune disorders [25]. The appropriate use of ani-
mal models is essential to ascertain the etiology of intes-
tinal inflammatory diseases, and is advantageous when 
elucidating the processes involved in the onset and pro-
gression of acute and chronic disease. Effectively applied 
animal models are instrumental to the development and 
prevention of appropriate mitigation strategies. Under-
standing the limitations, benefits, differences and simi-
larities between various animal models, and the chemical 
and biological methods that can be used to advance them 
is essential in the successful mechanistic understanding 
of disease.
Fig. 1 Systemic effects of intestinal inflammation. Multiple areas of 
the body can be influenced by intestinal inflammation. After stimula-
tion occurs in the intestine, circulating macrophages stimulate the 
release of cytokines. These cytokines not only promote macrophage 
and dendritic cell recruitment, but also stimulate the hypothala-
mus to alter food intake and increase the rate of metabolic activity 
through adrenal gland stimulation by ACTH and the production 
of corticosterone. Simultaneously, cytokines stimulate muscles to 
promote amino acid usage that can influence the liver and bone mar-
row. Acute-phase proteins released by the liver also influence other 
cytokine production, and the intermingled cycle continues as the 
intestinal mucosa is stimulated. ACTH adrenocorticotropic hormone
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Intestine and the immune system
The immune system within the intestine is a complex 
system; combining coordinated responses between the 
innate and adaptive immune systems within the intesti-
nal mucosa [26–28]. The innate and adaptive responses 
are composed of both cellular and non-cellular compo-
nents (Fig.  2). In the innate response, the non-cellular 
(humoral) components range from physical (epithelial 
lining, tight junctions, M cells) and chemical barriers 
(stomach acid, mucin) to antimicrobial proteins (cryp-
tidins, β-defensin α-defensin, heat shock proteins, 
compliment), cytokines and chemokines, Toll-like recep-
tors (TLRs), Nod-like receptors (NODs) and enzymes 
(peptidase, nuclease, lipase), and play a critical role in 
minimizing the number of infections the immune sys-
tem encounters [29, 30]. Cellular components of innate 
immunity include macrophages, mast cells, neutrophils, 
eosinophils, natural killer (NK) cells, NK T-cells, and 
dendritic cells, which can engulf and eliminate harmful 
pathogens [31]. Macrophages, and in particular dendritic 
cells, also act as antigen presenting cells (APC) which 
engulf the recognized pathogens and present their anti-
gens to components of the acquired immune system such 
as T-cells [32]. This process enables the two immune sys-
tems to operate in a coordinated manner.
Antibodies are the non-cellular components of the 
adaptive immune system produced by plasma B-cells and 
act to bind pathogens [33]. The pathogens are either neu-
tralized by agglutination with antibodies, or are targeted 
for destruction by the following methods: (1) activation 
of the compliment system; (2) opsonisation to granu-
locytes; or (3) release of cytokine cascades for NK cells 
Fig. 2 Small intestine mucosal immunity. Intestinal epithelial cells (IEC) make up the epithelial lining. The IEC are covered by mucus which serves 
as an important component of the innate immune system. In the large intestine mucus is divided into two distinct layers that vary in thickness ; the 
thicker outer layer being bacteria-rich and the thinner inner layer containing no or few bacteria  (not shown in image). The epithelium is composed of 
enterocytes and M cells, and these cells are held together by tight junction proteins. Of note, these cells and structures are also areas where bacteria 
can enter the host to induce inflammation and activate underlying immune cells. Cells important in immuno-surveillance, such as dendritic cells 
within the lamina propria can move through M cells or tight junctions in the IECs to sample luminal contents [28]. This information is presented to 
T-cell populations through the secretion of cytokines to facilitate cell maturation and proliferation [294]. Th1 (IFN-γ, IL-6, TNF-α) cytokines and Th17 
(IL-17A, IL-22) cytokines activate pro-inflammatory responses, Treg (IL-10, TGF-β) cytokines are anti-inflammatory and Th2 (IL-4, IL-5, IL-13) cytokines 
have both anti-inflammatory and pro-inflammatory potential. Immunoglobulin A (IgA) is released from plasma cells at intestinal crypts while anti-
microbial peptides (AMP) and defensins are released from Paneth cells (not shown) [28]. M cell microfold cell, TLR toll-like receptor, Th helper T-cell. 
Transcription factors; Foxp3 (Treg), T bet (Th1), Rorγt (Th17), Gata3 (Th2)
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[30]. The main lymphocytic cellular components of the 
adaptive immune system are composed of CD8+ and 
CD4+ T-cells. CD8+ T-cells are responsible for recog-
nizing and destroying organisms, primarily through the 
release of perforins and granzymes [28]. These function 
to create pores in the cell lipid bilayer and digest cel-
lular material to promote apoptosis, respectively [28]. 
Cytotoxic CD8+ T-cells can also enhance the release of 
effector cytokines, such as IFN-γ, TNF-α and TNF-β, 
which collectively promote macrophage activation and 
cell death [28]. CD4+ T-cells or helper T-cells are impor-
tant in the coordination of immune and inflammatory 
responses through the release of cytokines. There are five 
different subsets of CD4+ helper T-cells (Table 1) and the 
activation of the various helper T-cell responses is often 
determined by the type of pathogen affecting the host. 
For example, the Th1 response is mostly associated with 
infections by intracellular pathogens (i.e. viruses and bac-
teria), whereas Th2 responses defend against extracellular 
pathogens such as parasites [27]. Although the immune 
responses involved in intestinal inflammation are not the 
main theme of the current article, it is important to con-
sider the components of the innate and adaptive immune 
response when examining the causes and manifestation 
of intestinal injury and inflammation.
The intestinal microbiome
Microbial interactions and the intestinal environment 
are associated with the development and progression of 
many intestinal diseases.  The composition of the intes-
tinal microbiome can be influenced by diet, biologi-
cal and non-biological agents, host genetics, intestinal 
injury, infection, host stress and transmission of micro-
organisms from the vaginal canal during birth [34, 35]. 
Changes to the species diversity in the intestinal micro-
biome can affect intestinal inflammation, and studies 
investigating the addition of probiotic bacteria to the diet 
have concluded that specific bacteria have the ability to 
change the metabolic profile to support the growth of 
carbohydrate-reducing bacteria [36]. These bacteria con-
tribute to the increase of bioactive molecules beneficial 
for enterocyte growth and development [36]. Further-
more, the addition of probiotic cultures may preferen-
tially bind to the epithelial surface in the intestine and 
therein compete against and inhibit the attachment 
and subsequent colonization of pathogenic species, and 
this in combination with the consumption of prebiotics 
can also stimulate the growth of commensal bacteria to 
limit allochthonous   (i.e. non-resident)  bacteria [36]. In 
both human and non-human animal models, changes 
in intestinal bacterial communities can affect intestinal 
disease development [36]. In people, the colonic com-
munity is highly diverse within the Bacteroidetes and 
Firmicutes phyla, and a loss of diversity in these groups 
is commonly observed in patients with IBD, while oth-
ers report an increase in diversity and abundance in 
bacteria belonging to the Proteobacteria phylum during 
IBD related infections as well as acute enteric infections 
[37–39]. This shift in abundance of species that utilize 
carbohydrates for energy to species that utilize proteins 
for energy illustrates the relationship between metabolic 
activities of bacteria and intestinal disease [40, 41]. Bacte-
ria in the Firmicutes phylum are also important in health 
maintenance, as many bacteria within the class Clostridia 
have been implicated in immune development and main-
tenance of intestinal homeostasis [42]. Not only is the 
presence of specific bacterial groups paramount to the 
function of the intestine, but the interactions between 
the resident (i.e. autochthonous) bacterial species and the 
transient allochthonous bacterial species plays a signifi-
cant role in disease development. Colonization resistance 
is the phenomenon whereby the intestinal microbiome 
protects the host from pathogenic microorganisms [43]. 
Resident microorganisms have specialized methods that 
inhibit transient bacterial species that are often patho-
genic from occupying specific intestinal niches; the 
colonization resistance process limits the likelihood of 
pathogen attachment, growth and damage [44]. Along 
with the complex microorganism–microorganism inter-
actions, the host has developed methods directed by the 
innate immune response to mitigate bacterial-induced 
inflammation in the intestine at the epithelial-microbial 
interface [45]. Due to the complexity and involvement 
of highly prescribed processes specific to host-micro-
organism interactions, it is not possible to simulate the 
complex and interactive processes that occur within the 
intestine using in vitro animal models.
Animal models of inflammation
The intestine is a highly complex organ necessitating 
sophisticated and comprehensive animal models to study 
its function and disease. The diverse cell populations 
within the intestine contribute to this complexity. Addi-
tionally, the intestine is in contact with components of 










Tfh STAT3 Bcl6 IL-21
Th1 STAT4 T-bet IFN-γ
Th2 STAT6 Gata3 IL-4, IL-13
Th17 STAT3 Rorγt IL-17A, IL-17F 
Treg STAT5 Foxp3 IL-10, IL-35, TGF-β
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food digestion and maintains an environment rich in aer-
obic, obligate anaerobic, and facultative anaerobic bac-
teria. These bacteria frequently have modest to marked 
effects on the intestine and its physiologic and immu-
nologic functions. Identifying mechanisms involved in 
intestinal injury is necessary to develop mitigation strate-
gies to prevent disease. Studies using tissue samples from 
affected human beings would provide the most reliable 
data; however, there are indeed difficulties in acquiring 
human tissue for research including: the ethical use of 
collected human tissue; the often small sample size; the 
pronounced genetic variability between tissue from vari-
ous individuals; and the isolation of the intestinal tissue 
from the whole organism that can limit the use of human 
beings when investigating intestinal disease. As such, 
comparative whole animal models are needed to provide 
information representative of intestinal disease in people, 
and ideally these models provide large sample sizes and 
have genetically homogeneous backgrounds (i.e. geneti-
cally engineered rodent models).
A variety of mammalian models have been used to 
study acute and chronic intestinal inflammation. Mice are 
considered a good animal model as their intestinal devel-
opment is relatively similar to the human intestine and 
they have many of the same immune responses and genes 
[46]. Rat models have the advantage of being larger than 
mice thus allowing the acquisition of larger samples for 
analysis. Invertebrates, including nematodes and Dros-
ophila have also been used in intestinal studies, primarily 
to investigate mechanisms involved in innate immunity 
[47]. Zebrafish are extensively used to study both innate 
and adaptive immune responses [48]. Pigs are commonly 
used as an alternative monogastric mammalian model, 
as their intestinal function and morphology is similar to 
human beings [49]. Non-human primates (NHP) provide 
the best and most comparable data to people due to their 
high degree of genetic and physiological similarity to the 
human intestine. The use of NHPs in research however 
comes with considerable drawbacks—namely high costs, 
ethical considerations, and the potential hazards of car-
rying highly virulent zoonotic agents [50, 51]. Other 
mammals have also been used to investigate intestinal 
inflammation including rabbits, guinea pigs [52], and to 
a lesser degree, ruminants. Dogs develop IBD and exhibit 
similar gene dysfunction to people with CD, and many 
studies have used canine models to identify biomarkers 
of IBD [53, 54]. Collectively, the above models can be 
used to determine the mechanisms in the development 
and progression of intestinal disease. Moreover, rela-
tively sophisticated surgical models, such as the intestinal 
loop technique have been developed to further elucidate 
mechanisms. Although no single animal model is perfect 
for studying all components of intestinal inflammation, 
each possess unique features to explore the various 
aspects of intestinal injury and disease.
Mice
Mice are the most commonly used animal model for 
intestinal studies, and genetically engineered mice are 
particularly important in studying intestinal inflamma-
tion [55]. There are many reviews that summarize and 
discuss the use of genetically modified murine models to 
study intestinal disease [56–58], and this section of the 
review will focus on the advantages and disadvantages of 
using rodent models. A variety of gene knockout mod-
els are available to study innate and adaptive immune 
responses during intestinal infection (Table  2). Their 
genetic lines can be modified to produce phenotypes that 
investigate specific aspects of intestinal inflammation 
associated with adaptive and innate immune responses, 
ranging from the activation of proteins involved in patho-
gen recognition to the activation of effector cells neces-
sary to trigger both cell-mediated and humoral immune 
responses. Thus, the rapid expansion in the use of geneti-
cally modified mice  has allowed investigators to study 
various aspects of intestinal inflammation and disease 
(Table 2).
Certain genetic lines of mice are more suited to inves-
tigate specific conditions of acute and chronic enteritis, 
and it is imperative to choose genetic strains of mice 
that best represent the aspects of disease being investi-
gated. For example, IL-10 knockout mice with a C3H and 
BALB/c background are known to develop spontaneous 
colitis more frequently than wild-type C57BL/6 mice 
[56]. Alternatively, the C57BL/6 background is more 
susceptible to Th2 mediated colitis than the BALB/c 
and C3H/HeJ backgrounds, and TCRα chain deficient 
C57BL/6 mice are more susceptible to colitis than their 
BALB/c and C3H/HeJ counterparts [56]. Moreover, it 
is known that chemical agents used to induce chronic 
intestinal inflammation can be affected by the genetic 
background of the mouse. For instance, trinitrobenzene 
sulfonic acid (TNBS), a chemical used to incite CD-like 
symptoms in mice, depends largely on genetic back-
ground; in SJL/J, C3HeJ and BALB/c mice treated with 
TNBS, mice develop CD-like intestinal lesions, whereas 
C57BL/6 mice under the same conditions remain rela-
tively unaffected [56]. Similarly, Swiss Webster and C3H/
HeJ mice develop UC-like lesions after the administration 
of dextran sulphate sodium (DSS), and C57BL/6 mice 
treated with DSS display less tissue injury [59]. The abil-
ity to genetically modify mice, and to a lesser extent rats 
and other rodents, is a crucial asset for elucidating mech-
anisms of acute and chronic intestinal inflammation.
The majority of genetically engineered rodent models 
have been developed solely for research purposes and 
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many knockout models are designed to study the loss 
of regulatory gene function, or the over stimulation of 
pro-inflammatory effector molecules (Table  2). Immu-
nocompromised genotypes have also been very useful in 
the investigation of colitis-inducing immune responses. 
Immunocompromised mouse models include severe-
combined-immunodeficient (SCID) and Rag−/− mice 
combined with the supplementation of CD4+CD45RBhigh 
naïve T-cells which lack the ability to produce functional 
B and T lymphocytes. In these models, the supplemented 
naive T-cells interact with antigens and become acti-
vated as colitogenic T-cells and result in chronic trans-
mural inflammation in both the small and large intestine 
[60, 61]. Other strategies such as the use of microRNAs 
to target genes such as tumour suppressor genes have 
also been suggested as quick and efficient methods to 
induce colorectal and colitis-associated cancer models 
[62]. To investigate inflammatory responses triggered 
by microbial components, germ-free and gnotobiotic 
mice provide an environment where there is no micro-
bial colonization within the intestine (i.e. axenic), or the 
intestine is colonized with a relatively small number of 
defined bacteria such as the Altered Schaedler Flora [63]. 
Both microbial conditions have proved valuable in eluci-
dating important aspects of host-microorganism interac-
tions [64]. A number of researchers have attempted to 
create ‘humanized’ mice, which either have human genes 
knocked into their genomes, or have established a human 
microbiome in germ-free mice via the transplantation of 
bacteria within human fecal material to create models 
potentially more applicable to human diseases [65, 66]. 
Advancements in genetic engineering and the use of the 
murine animal model have provided a versatile platform 
for mice in the elucidation of mechanisms necessary to 
understand intestinal disease.
Other qualities such as the similarities between the 
murine and human microbiome, immune responses, as 
well as the monogastric anatomical structure are impor-
tant considerations when choosing mice to investigate 
intestinal injury. Mice share many specific intestinal 
genes with people, and mapping of the mouse genome 
and comparative genomic studies concluded that over 
90 % of human and mouse genes are shared among the 
two species, and approximately 80 % of the mouse genes 
have a human orthologue [46, 67]. Furthermore, human 
and murine intestinal communities exhibit the same 
diversity of species within the Firmicutes, Bacteroidetes, 
and Proteobacteria phyla [68]. The mouse gastrointesti-
nal tract is also anatomically and functionally similar to 
human beings, and importantly, mice have many features 
analogous to the adaptive immune response such as the 
presence of similar populations of B-cells, T-cells, and 
isotype antibodies [69]. Other salient advantages of mice 
as an animal model includes their small size (e.g. effi-
ciency of husbandry), their relatively short estrous cycles 
and gestation period, and their large litter sizes [70].
A broad armamentarium of analytical tools is required 
to comprehensively investigate intestinal inflammation. 
Indeed, analysis tools such as monoclonal antibodies, 
accurately designed PCR primers and cell assays are nec-
essary. There are many commercially available diagnostic 
biomolecules available to study inflammation in rodents, 
and rodent models having their entire genome sequenced, 
possess a large repertoire of available biomolecules and 
Table 2 Summary of common knockout genes used in murine models of intestinal inflammation
Genes Function Immunity affected Reference
IL-10 Cytokine involved in anti-inflammatory and regulatory pathways Adaptive [57, 64, 296, 297]
IL-23R Th17 cytokine; T-cell differentiation Adaptive [296]
CD4+CD25+ Regulatory T-cell adaptor glycoproteins Adaptive [296, 297]
NOD2/CARD15 Intracellular bacterial peptidoglycan receptor/apoptotic protein Innate [296]
TGF-β1 Regulatory cytokine; inhibits effector T-cell development, downregulates immune response Adaptive [297]
RAG Protein; B and T lymphocyte maturation Adaptive [57, 64, 296]
ATG16L1 Autophagy gene involved in pathogen regulation Innate and adaptive [296]
APCmin/+ Gene; Β-catenin regulator involved in CRC development Innate [64]
IL-2 Pro-inflammatory cytokine Adaptive [57]
TNF-α Th1 cytokine; apoptotic signal activation Innate and adaptive [57]
STAT3 Signalling molecule; intestinal mucosa regeneration post injury Adaptive [296]
NFκB Transcription factor; pro-inflammatory cytokines and cell survival factors Adaptive [57, 296]
Muc2 Gene; mucin, main constituent of intestinal mucus, physical barrier formation Innate and adaptive [296]
IFN-γ Pro-inflammatory cytokine Innate and adaptive [57]
MyD88 Transcription factor; signalling molecule for TLR and NFκB Innate and adaptive [64]
TLR Family of receptors for identification of various microbial surface proteins Innate [64]
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reagents [67, 71]. Many analysis techniques such as 
cytokine arrays, fluorescence in situ hybridization meth-
ods, and sequencing platforms have well developed and 
quality checked methodologies that work well with tissue 
isolated from rodents. Using established biomolecules 
in conjunction with specialized methods and techniques 
tailored to mice allows researchers to investigate a broad 
range of detailed and specific cellular processes involved 
in intestinal inflammation.
Although there are many similarities between mice 
and human beings inlcuding gene homology, immune 
and intestinal function, physiology [67], and intestinal 
bacterial community structure, there are some signifi-
cant disadvantages to employing mice and other rodent 
models to study aspects of human intestinal inflam-
mation. Importantly, the intestinal lesions observed in 
people with IBD are not identical to lesions observed in 
mice following exposure to chemical agents. For instance, 
although the administration of DSS to mice induces 
chemical injury to the epithelial lining which mimics 
mucosal injury observed in people with UC [72], the 
severity of the lesions are not consistently representa-
tive of human beings with UC. Moreover, there are also 
differences between the murine and human expres-
sion of TLR2, TLR3, TLR4, and TLR9. Murine models 
exhibit strong mRNA expression patterns of these TLRs 
in macrophages following exposure to bacterial LPS [73]. 
In contrast, TLR3 expression in people is restricted to 
dendritic cells, whereas TLR2 and TLR4 expression are 
restricted to myelomonocytic cells [73, 74].
Behavioural patterns in mice also impact intestinal dis-
ease and can potentially confound the study of diet on 
the induction and progression of intestinal inflammation. 
Coprophagy, a nocturnal behaviour in mice, is important 
for re-ingestion of nutrients and can affect dietary bal-
ance, microbial populations, and potentially affect intesti-
nal health [75]. In contrast, coprophagy is not considered 
a normal behaviour in people, and thus extrapolation 
of dietary effects on intestinal inflammation in mice to 
human beings can provide inaccurate interpretations. 
Another potential disadvantage of using rodent models 
and specifically mice to study intestinal inflammation is 
the relatively small sample sizes that can be harvested 
from mice. Often, this requires that substrates or tissues 
are pooled from multiple animals for analyses. The neces-
sity of pooling samples requires that multiple animals are 
used for the study, and this subsequently increases the 
cost and fails to reduce the numbers of animals required 
for the research—an important ethical consideration in 
animal experimentation. The small size of mice can also 
limit the implementation of surgical procedures, and the 
use of radiotelemetry devices, endoscopes, and ultra-
sound equipment [76, 77]. Although there are drawbacks 
to using mice, the multitude of advantages make mice 
an excellent choice to investigate processes involved in 
intestinal inflammation of mammals.
Rats
 Rats are also frequently employed as an animal model to 
study intestinal injury and disease. Many of the chemicals 
used to incite acute inflammation in murine models are 
also useful in rat models. Interestingly and as an example, 
the TNBS model was initially developed for rats, and it 
is currently widely used in other organisms such as mice 
and zebrafish [78–80]. Furthermore, other chemical incit-
ants such as DSS (a model for IBD) also induces injury 
to colonic tissue similar to the tissue injury observed in 
mice [72, 81]. One of the most commonly used geneti-
cally modified rat models is the transgenic HLA-B27 
model of colitis, which spontaneously develops gastro-
intestinal inflammation including gastroduodenitis and 
colitis, as well as arthritis and spondylitis [82, 83]. Finally, 
an alternate rat model of acute inflammation has also 
been established using the biological incitant Campylo-
bacter jejuni, suggesting that both chemical and biologi-
cal agents are useful to induce colitis in the rat animal 
model [84]. Rats are often used in nutritional studies. For 
example, researchers have utilized the rat model to inves-
tigate the impact of fiber-rich diets on intestinal micro-
bial community structure [85, 86]. These groups have 
investigated changes in community structure observed 
in feeding trials in rats, and have importantly been able 
to compare their observations with similar findings in 
swine. This suggests that nutritional studies in the rat 
intestine can be compared to other non-rodent monogas-
tric animal models [85].
Although both rats and mice are considered to pri-
marily be cecal fermenters, recent research has shown 
that a considerable amount of fermentation occurs in 
the rat colon as well [87]. As such, rats could be a model 
to examine colonic changes associated with intestinal 
inflammation or neoplasia. It has been shown that muta-
tion of the APC gene induces spontaneous development 
of tumours along the intestinal tract of rodents [64]. 
Interestingly, mutations of the APC gene in rats induces 
localized tumour development within the colon and 
rectum, an observation that differs from mice whereby 
tumour development is generally restricted to the small 
intestine. Thus, the rat APC mutant gene model would 
be a better choice for investigating the pathophysiology 
of colorectal cancer (CRC) in people as compared to the 
mouse model [88].
Another advantage of rats compared to mice is their 
relatively large body size and larger intestinal tract [88]. 
As an example, the larger physical size of the rat allows 
for better experimentation with the chemical incitant 
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TNBS, as TNBS induces more pronounced intestinal 
injury when administered rectally (opposed to per os). In 
as such, this procedure is much easier to perform in the 
larger rat model as compared to mice. Finally the larger 
intestinal tract of the rat also allows for more tissue to 
be harvested, and would allow more data to be collected, 
and limit the need to ‘pool’ tissue samples as is often 
required when harvesting tissue from mice.
Although the larger size of the rat has several advan-
tages over the smaller mouse, in general more investi-
gations into the pathophysiology of intestinal disease in 
people employ mice as the primary rodent model [89], as 
underscored by the utility of IL-10 knockout mice used 
to study colitis [90, 91]. Furthermore, murine models 
have a considerably higher amount of genetically altered 
and highly conserved inbred strains to study intestinal 
inflammation when compared to rats, which are often 
composed of outbred stains (Wistar and Sprague–Daw-
ley rats) and contain a less conserved genetic background 
[89]. Despite this, the rat is still a valuable animal model 
to study intestinal inflammation and it is conceivable that 
overtime, there could be an increase in the numbers of 
analytical tools and reagents available for rats, making 
rats an even more effective animal model to study intesti-
nal inflammation in people.
Nematodes and insects
Nematodes are not considered a ‘conventional model’ 
to study mammalian intestinal inflammation; however, 
nematodes can provide insights into the mechanisms 
involved in innate immunity and defence. Although 
nematodes are small and lack an adaptive immune sys-
tem, they share several characteristics that are similar to 
the mammalian intestine  including: a modified innate 
intestinal immune system; production of antimicrobial 
peptides; similar signaling pathways; and a plethora of 
complex intestinal bacteria-enterocyte interactions [47, 
92]. To exemplify this, Caenorhabditis elegans has been 
used to examine host-microbiome interactions in the 
intestine at the apical surface of epithelial cells [93]. In 
its natural habitat, C. elegans can be isolated from rotting 
fruit in the soil and is known to consume bacteria as its 
main food source [94]. Bacteria belonging to the Proteo-
bacteria phylum act as commensal residents within the 
C. elegans intestine, and some species such as Salmonella 
enterica serovar Typhimurium, and Yersinia pestis have 
been suggested to cause injury to the nematode intestine, 
similarly to injury observed in the mammalian intestine 
[94, 95]. Notably, this intestinal model has been used 
to examine bacterial populations required to maintain 
intestinal homeostasis and to investigate mechanisms of 
epithelial defense [93, 95]. C. elegans has been used to 
visualize events involved in the induction of necrotizing 
enterocolitis through the analysis of serine and proteases 
inhibitor activity on epithelial cell function [47]. The 
pathogenicity and intestinal injury caused by Listeria sp., 
Salmonella sp. and Shigella sp. has also been investigated 
using the C. elegans model [96]. As an example, Listeria 
monocytogenes induces intestinal epithelial changes in C. 
elegans by processes that are independent of traditional 
bacterial translocation through goblet cells or epithelial 
cell junctions [97].
Similarities are also observed when comparing nema-
tode and mammalian signalling pathways, protein secre-
tion, and expression of transcription factors [98]. As 
examples, the C. elegans NSY-1/SEK/PMK-1 MAP kinase 
pathway has been identified as a mammalian MAP kinase 
ortholog [93], and studies examining kinase activation 
identified this pathway in the C. elegans NF-κB response 
parallel to mammalian innate immune system activa-
tion independent of TLR signalling [93]. Another advan-
tage of using C. elegans is that it is translucent and this 
characteristic enables investigators to visualize real-time 
events involved in digestion and innate immune function 
[47]. This attribute has been useful in measuring tempo-
ral changes involving intestinal cell integrity, and the sub-
sequent progression of intestinal inflammation following 
challenge with pathogenic S. enterica or Escherichia coli 
species [95, 96].
Insects possess many of the same attributes as nema-
todes making them a valuable model to study intestinal 
function. Recently, the fruit fly Drosophila melanogaster 
has been used to study the mechanisms involved in 
intestinal function and disease. Specifically, the D. mela-
nogaster model has been used to examine changes in the 
innate immune response as it relates to chronic inflam-
mation and cancer development [99]. Drosophila can 
provide a highly applicable system to study mechanis-
tic changes in the host genome. The innate immune 
response of Drosophila is often associated with antimi-
crobial peptides (AMPs) and the reactive oxygen species 
(ROS) response produced by its epithelia, followed by 
immobilization of phagocytic haemocytes which engulf 
foreign materials [100]. Specialized Drosophila cytokines 
such as the Toll ligand, Spätzle (Spz), and unpaired 3 
(Udp3) also contribute to an immune response, whereas 
the specialized Imd pathway responds to Gram nega-
tive bacteria and activates antibacterial peptide genes 
through NF-κB-like proteins [100]. Presently, cell signal-
ling pathways involving innate immune functions have 
been studied in the Drosophila intestine. Drosophila pos-
sess an immune deficiency pathway that is functionally 
similar to the NF-κB signalling pathways in mammals, 
and uses the dual function NADPH oxidase (DUOX) 
pathway to produce ROS as a means of bactericidal 
defence within the intestine [101]. Importantly, these 
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events in the Drosophila intestinal epithelium are mecha-
nistically similar to defences observed in human beings; 
furthermore, components of the epithelial architecture 
of the Drosophila intestinal epithelium are also similar to 
people [100, 101]. Structurally, the epithelial monolayer 
and brush border, enterocytes, and crypts of Drosophila 
are also comparable to mammals [102]. Intestinal epithe-
lial cell regeneration and differentiation in Drosophila is 
also homologous in mammalian cells, and is exemplified 
in the Notch, K-Ras/Ras, JNK, and Wnt/wg signalling 
pathways [102].
Caenorhabditis elegans and Drosophila can be used as 
effective invertebrate models for identifying early pro-
cesses involved in the initiation and progression of innate 
aspects of intestinal inflammation [103], cell signalling, 
epithelial barrier function, and the impact of bacterial 
populations on intestinal physiology [47, 95]. A major 
limitation to the use of these invertebrate models is the 
lack of an adaptive immune response and some cellular 
processes that are present within the mammalian intes-
tine [104]. This is underscored by the induction of intes-
tinal injury in the C. elegans model by L. monocytogenes 
employing mechanisms that do not involve translocating 
through goblet cells or epithelial junctions, a feature that 
is employed within the mammalian intestine [97]. Fur-
thermore and in general, the C. elegans model may not 
be ideal to investigate host-microbiome interactions with 
respect to human pathogens, as many intestinal bacteria 
and other microorganisms are harmful to the C. elegans 
intestine [105]. This observation is highlighted in a study 
that challenged C. elegans with either commensal E. coli 
or Citrobacter rodentium in the presence of Giardia 
duodenalis, which resulted in increased mortality in the 
treated worms. This indicates that caution should be 
used when employing C. elegans to investigate the inter-
actions between the intestinal microorganisms and the 
host [106]. Finally, a potential limitation of insect mod-
els is that portions of the foregut and hindgut are lined 
with chitin. Certain holometabolous insects produce 
a peritrophic matrix that is functionally similar to the 
intestinal glycocalyx of mammals and serves to protect 
the gut from mechanical damage and also acts as a bar-
rier against the invasion of microorganisms [107]. Impor-
tantly, the peritrophic matrix is composed of microfibrils 
rich in chitin, a product that is not present in the mam-
malian intestine [107]. Thus, insect models may not be 
appropriate for studying either the physiological func-
tions of the intestinal glycocalyx or microbial interactions 
with the glycocalyx.
Fish
Zebrafish (Danio rerio) have been used to model the 
human intestine for many years, and although this is a 
non-mammalian vertebrate model, it is a highly versa-
tile model that provides researchers with the option to 
study both innate and adaptive immune responses [48]. 
Zebrafish are considered by many to be superior to inver-
tebrate models as they have a larger repertoire of organs 
that exhibit pathologic changes. Similarly to C. elegans, 
they have a transparent embryo and larvae, relatively 
simple husbandry requirements, and are highly fecund 
[108]. The zebrafish intestine possesses similar cell types 
to mammals such as absorptive enterocytes, endocrine 
and goblet cells, a functional brush border with micro-
villi, and an epithelium that is continuously sloughed off 
into a luminal space and regenerated in a manner paral-
lel to the murine and human intestine [109]. Zebrafish 
do not have a defined stomach, therefore its strengths 
as a nutritional model are limited as most protein and 
fat absorption occurs in the lower intestine rather than 
in the small intestine [109]. Despite this limitation, the 
zebrafish model has proven useful for studies of intesti-
nal motility and peristaltic events through a mutation 
that leads to the loss of enteric neurons [108]. Most stud-
ies examining inflammation events in zebrafish have uti-
lized chemical incitants, namely TNBS and DSS [110]. 
The zebrafish model has been well established to study 
host-microorganism interactions and bacterially trig-
gered immune responses [111]. The establishment of a 
germ-free zebrafish model has enhanced its ability to be 
applied to microbiome research, and researchers have 
used germ-free fish to understand and compare the rich-
ness and abundance of microbial communities [112, 
113]. Significantly, the adaptive immune response in 
zebrafish develops to maturity in approximately 3weeks, 
and the use of zebrafish at 3-weeks of age or younger 
allows researchers to study innate responses without 
the interference of the adaptive immune response [48]. 
As zebrafish possess a functional innate and adaptive 
immune response, their use in combination with larger 
animal models can be very advantageous to elucidate 
the role of the intestinal microbiome on enteric disease. 
Applications of the zebrafish model to further understand 
the effects of acute and chronic inflammation on intesti-
nal cells can be very useful, and it is expected that this 
model will become increasingly utilized once more bio-
molecules and techniques are developed. The zebrafish 
intestine has the added advantage of being homologous 
to the human intestine structurally, and the ability to use 
direct live imaging to view the epithelial cells in real-time 
during infection significantly increases the effectiveness 
of this model.
Pigs
The pig is an excellent mammalian model to study the 
mechanisms involved in acute and chronic intestinal 
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injury and inflammation, as the intestine is anatomically 
and functionally similar to the human intestine [49]. The 
anatomic structure of the pig gastrointestinal tract, in 
particular the stomach and small intestine, is analogous 
to the arrangement in human beings and differs only by 
the spiral orientation of the pig colon and the lack of an 
appendix [114]. Despite this, primary intestinal functions 
such as nutrient and water absorption and microbial fer-
mentation are still comparable to the human intestine 
[114, 115]. Additionally, intestinal digestive enzymes, 
secretory proteins and the microbiome within the pig 
intestine are also comparable to people, facilitating the 
examination of the relationship between microbial com-
munities, diet and intestinal health [114, 116]. The pig 
model has also been used extensively to replicate the 
human microbiome in the pig intestine through fecal 
transplantation procedures [115]. Several studies have 
also examined the pre-colonization of piglets with probi-
otic and avirulent bacterial strains common to the human 
microbiome, and concluded these strains were protective 
against subsequent infection with pathogenic bacteria 
[117, 118]. Many of the immune cells and processes of 
the innate and adaptive immune system, namely popula-
tions of mucosal and intraepithelial B and T lymphocytes 
and the recognition of activators of innate immunity (i.e. 
LPS and nucleic acids) by macrophages, are also compa-
rable to those in human intestinal immunity [119, 120].
Although pigs are an excellent animal model to study 
intestinal inflammation of people, there are variations in 
the porcine adaptive immune response. Most notably, the 
pig has an abundance of intraepithelial and plasma γδ 
T-cells in comparison to mice and human beings [121]. 
In human and murine models, it is uncommon to find 
mature, resting CD4+CD8+ T-cell subsets in peripheral 
blood [120], however in pigs, cattle and sheep these pop-
ulations are highly elevated and are suggested to increase 
T-cell memory during infection [122]. Furthermore, the 
high number of γδ T-cell receptors (TCRs) in the pigs 
make it an effective immune model to study this T-cell 
lineage, as the low presence of γδ TCRs in the human 
and mouse models proved to be inefficient to under-
stand how these cells rapidly respond to bacterial anti-
gens in the host intestine [123]. Although in pigs more 
CD4+ T-cells also co-express CD8+ TCRs, similarities 
between the murine, human and porcine Treg response 
exist regarding the CD4+CD25+high T-cell population 
and the increase in IL-10 expression via Foxp3 regulation 
in all three species [124]. Differences in immunoglobu-
lin expression also exist; in the human immune response 
IFN-γ increases the expression of IgG1, whereas in swine 
Th1 cytokines such as IFN-γ, IL-12 and IL-10 promote 
IgG2 expression [125]. In addition, expression of Th2 
cytokine IL-4 is downregulated in pigs, as compared to 
human beings and mice, which show increased expres-
sion of IL-4 when induced [119].
The use of pigs as a large animal model enables 
researchers to harvest large amounts of tissue, a dis-
tinct advantage when investigating intestinal inflam-
mation. The size, slow growth rate and relatively slower 
reproductive rates of the pig however, are unfavourable 
qualities when studying intestinal inflammation relative 
to other animal models. For instance, commercial swine 
have rapid growth rates and can gain 90 kg of weight in 
18  weeks [126]. These large animals also require large 
housing facilities and husbandry costs compared to 
smaller rodent and invertebrate models. Additionally, the 
114  day gestation period in swine is much longer than 
the 21  day gestation period in mice [127], and sexual 
maturity is reached at 6–8  months in swine, compared 
to 6–8 weeks in mice [128]. Collectively, the reproductive 
biology, increased costs of housing and the overall size 
of pigs can limit their use as an intestinal inflammation 
model in comparison to rodents, invertebrates and fish. 
Despite the drawbacks (e.g. cost, husbandry challenges, 
spiral colonic anatomy, large cecum, and lymphocyte 
variations), pigs are considered to be a good large animal 
model to study intestinal inflammation of people.
Non-human primates
Non-human primates (NHPs) are considered the best 
animal model to study the mechanisms involved in 
acute and chronic inflammation, as there are irrefuta-
ble similarities to human intestinal physiology, function, 
immunology, and the intestinal microbiome. Macaques 
and tamarins are most commonly used to study mecha-
nisms involved in both the pathogenesis and treatment of 
intestinal disease [129]. Interestingly, these NHPs often 
develop spontaneous colitis and subsequent colon can-
cer following extended periods of confined captivity, and 
thus are good models to examine the de novo generation 
of intestinal inflammation and neoplasia [129–131]. For 
instance, Gozalo et  al. [130] demonstrated that tama-
rins held captive for an average of 100  months develop 
terminal spontaneous ileitis that initially presents as 
chronic diarrhea 3–6  months prior to the confirmation 
of ileitis. Other researchers have shown that tamarins can 
develop spontaneous and chronic colitis around 2 years 
of age [132], and studies suggest that stress in tamarins 
and the ambient temperature of their housing facilities 
during captivity may contribute to the development of 
colitis [133, 134]. Although many of the cellular mecha-
nisms involved in the development of spontaneous coli-
tis remain unknown [135], Ramesh et al. [136] examined 
the cytokine production in gut-associated lymphoid tis-
sue (GALT) of rhesus macaques exhibiting signs of per-
sistent diarrhea. These macaques with enterocolitis had 
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higher amounts of TNF-α and IL-1α in the GALT and 
non-intestinal lymphoid tissue, an observation consistent 
with human patients with necrotizing enterocolitis [131, 
136, 137].
Non-human primates are also used to investigate the 
effect of microorganisms on the development of intesti-
nal inflammation, and have demonstrated that intestinal 
bacteria can influence the onset of disease [138]. Impor-
tantly, the microbiome in NHPs, rodents, zebrafish, and 
human beings all possess similarities to one another, and 
imbalances made in the intestinal communities can lead 
to disease. Not only are the populations of the bacte-
rial communities critical to maintaining homeostasis in 
the intestine, but species of Archaea within the intestine 
also contribute to the maintenance of a well-functioning 
microbiome. Investigations have identified methane-
producing Archaea species and sulphate-reducing bac-
teria (SRB) collectively produce metabolic by-products 
associated with poor colonocyte health and function 
[41]. Furthermore, the severity of disease increased with 
higher amounts of SRB. As these bacteria increased in 
number, the hydrogen sulfide concentration in the colon 
also increased [139], suggesting a connection between 
methane-producing Archaea and SRB with intestinal 
health. Further, Macaca sp. have been used to examine 
the pathophysiology of C. jejuni infection, and it was 
shown that neutrophil and lymphocyte infiltration in 
the mucosa along with bloody stool and watery diarrhea 
were observed, aligning with the tissue changes of acute 
colitis observed in human campylobacteriosis [140]. 
Finally, rhesus macaque populations have also shown 
that species-specific Helicobacter spp. infections induce 
colitis [141], while Shigella flexneri infection in rhesus 
macaques has been associated with mucosal invasion and 
marked imbalances in electrolyte transport—manifesta-
tions similar to shigellosis in people [131].
The intestinal environment is in a constant state of flux 
and as such is either in a state of immunological quies-
cence or activation, and it has become clear that altera-
tions of these states can impact brain function and the 
mental health of the host. As such, researchers are now 
using animal models to examine the effect of the intes-
tine on mental health. Non-human primates can be 
employed to investigate the relationship between the 
intestinal microbiome, the intestinal nervous system, 
and the impact on host well-being. The gut-brain axis is 
a functional link between the intestine, the autonomic 
nervous system, and the higher functions of the brain. 
Innervation of the autonomic nervous system has shown 
that perturbations in the intestinal microbiome influ-
ence brain function and behavior, and thus can result 
in changes in feeding behavior, anxiety-like behaviour, 
stress, depression, and pain perception [34]. Many of 
these functional changes are observed in patients suffer-
ing from IBD and IBS [21, 142]. Although mice have also 
been used to study certain aspects of the gut-brain axis 
[143], NHPs likely are the best model to study neurologi-
cal activity for human beings. Many NHPs characteristi-
cally develop deeper social bonds and display behaviours 
indicative of higher human-like intellect, giving them 
preference over the mouse and pig animal models for 
brain-related investigations.
The use of NHPs appears to be the most representa-
tive animal model to simulate intestinal inflammation in 
people. This model however, has considerable drawbacks. 
Most notably, the ethical use of highly intelligent animals 
closely related to human beings is controversial, and gen-
erates charged discussion between the scientific commu-
nities involved in animal research and the general public. 
Many people also believe NHPs such as the near extinct 
African Great Ape species should be banned from scien-
tific research [144]. NHPs also require specialized hous-
ing facilities with an extensive and expensive biosecurity 
infrastructure, as well as elaborate equipment for envi-
ronmental enrichment [145]. Moreover, several species 
of NHPs are large (gorillas, chimpanzees and orangutans) 
and can be potentially intractable and dangerous, requir-
ing animal care staff and veterinarians with specialized 
training in animal husbandry, safety, and disease control. 
Furthermore, NHPs may carry zoonotic organisms that 
are highly pathogenic and easily transferable to people. 
One of the most well-known, potentially fatal pathogens 
carried by NHPs is Cercopithecine herpesvirus (B virus) 
[146], and although it is relatively innocuous in monkeys, 
people who are exposed to the virus through secretions 
from bites or scratches can develop a fatal form of viral 
myeloencephalitis [146].
Other animal models
There are other less frequently used animal models 
employed in intestinal inflammation and disease stud-
ies. Gnotobiotic juvenile beagles have been used to 
study colitis induced by C. jejuni, with results indicat-
ing mild colitis develops in the absence of mucosal infil-
tration [147]. More recent studies have used German 
Shepard dogs to study canine IBD, and attempt to make 
comparisons between cytokine expression in the dog 
intestine and alterations in gene expression observed in 
human patients with IBD [148, 149]. Sheep as a ruminant 
model have also been used for intestinal investigations, 
but unlike monogastric species ( Homo sapiens, NHPs, 
rodents, and pigs), the majority of bacterial fermenta-
tion of carbohydrates tends to occur in the rumen and 
not in the large intestine [150]. As such, ruminants are 
not ideal models to use for microbiological and nutri-
tional studies of intestinal inflammation in people due to 
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the importance of the rumen in ruminant nutrition; the 
rumen also harbors a microbial community that differs 
greatly from the large intestine of monogastric animals. 
Most research involving nutrition in ruminants focusses 
on the rumen. The ruminant intestine remains an area 
less studied, although a few studies have utilized the fetal 
ovine intestine for inflammation-based research [151, 
152]. Some research has suggested that the presence 
of Mycobacterium avium subspecies paratuberculosis 
(Map), a bacterium that causes intestinal disease in cattle, 
can be associated with people with CD [153]. Although 
most studies provide contradicting evidence regard-
ing the presence of Map in CD patients, some research-
ers have suggested that this cattle enteric pathogen can 
contribute to the onset of CD in human tissue, and vice 
versa [154, 155]. The bovine animal model has also been 
used to study non-typhoid enteric infection induced by 
S. enterica serovar Typhimurium, since wild-type mouse 
models tend to develop a fatal systemic form of typhoid 
following challenge with the bacterium [156]. A few stud-
ies have used sheep as comparative models for human 
studies, using intestinal loops in neonatal sheep to study 
mucosal immune function [157]. Although this model is 
good for studying the impact of pathogens on intestinal 
injury (Fig. 3), this particular model was limited to exam-
ining intestinal changes in the upper small intestine, and 
did not examine the interactions within the lower intes-
tine, diet (i.e. ingesta), and microbial colonization [157]. 
The rabbit is another animal model that has been used to 
study colitis. In one study, bacterial muramyl dipeptide 
was emulsified with Freund’s incomplete adjuvant and 
administered rectally into the submucosa for a period of 
1 month [158]. Following muramyl dipeptide administra-
tion, mononuclear cell infiltration, lymphoid aggregation, 
and transmural inflammation were observed in the rabbit 
colon [158]. Of late, preterm rabbit models have been 
used as a method to understand physiologic and biologic 
changes associated with intestinal dysfunction, neona-
tal necrotizing enterocolitis, and rectal-anal obstruction 
[159]. Rabbits and guinea pigs have also been used to 
study intestinal lesions resulting from the administration 
of common chemical incitants (to be discussed later in 
the review) of intestinal inflammation [52, 56].
Surgical models
A number of surgical models have been developed to 
study inflammation. Surgical models possess a multitude 
of advantages including the ability to manipulate physio-
logical and microbiological processes within the intestine 
and circumvent some of the ethical issues encountered 
when working directly with human subjects. Also, sur-
gical models deliver a number of logistical advantages 
including the ability to deliver and localize treatments, 
and to measure treatment effects in a highly prescribed 
manner. An example of a model that has been used to 
manipulate physiological and microbiological process is 
the cecectomy model in mice. As the cecum is a major 
site of complex carbohydrate fermentation in mice, surgi-
cally removing the cecum significantly alters the micro-
bial community structure and fermentation processes 
[160, 161] and also affects colonization resistance. Sur-
prisingly, this model has not been extensively used to 
study colonization resistance processes [160], nor has it 
been applied to pigs or ruminants to date.
Xenografts involve the transplantation of fetal intesti-
nal segments from one species into a different recipient 
species. The recipient mice are B- and T-lymphocyte 
deficient (e.g. SCID, and NOD SCID gamma mice) as 
the use of immunodeficient mice is necessary to pre-
vent graft rejection. The transplant tissue is implanted 
Fig. 3 Sheep intestinal loop model. Ovine ileal segments inoculated with a Campylobacter jejuni 81-176 or b phosphate buffered saline and 
harvested 48 h post inoculation. Campylobacter jejuni treated intestinal loops are markedly edematous, congested, and presented with numerous 
fibrino-hemorrhagic foci of mucosal necrosis
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under the skin of the back on recipient mice, and allowed 
to grow. Treatments are then injected directly into the 
lumen of the graft via a hypodermic needle. Transplanta-
tion of human, rat, and bovine intestinal xenografts has 
been successfully performed [162–164], and we recently 
and successfully transplanted porcine fetal intestines into 
SCID mice. After transplantation of the xenograft, the 
species-specific integrity of the epithelium of the trans-
planted tissue is thought to be retained, however chi-
meric tissue can form within the submucosa and lamina 
propria [165]. Xenograft models are considered to be 
axenic, but care must be taken to avoid the introduction 
of contaminant bacteria during the inoculation proce-
dure. The intestinal xenograft model has been used to 
measure pathologic metrics incited by a variety of biotic 
incitants of inflammation including Clostridium difficile 
toxin A and B [166], Cryptosporidium parvum [167–169], 
Entamoeba histolytica [170–173], Enterohemorrhagic E. 
coli (EHEC) [163, 174], Helicobacter pylori [175], Map 
[176], rotavirus [174], Salmonella typhi [177, 178], and 
S. flexneri [179]. Metrics of inflammation in xenografts 
have focused on histopathologic changes, loss of barrier 
function, and differential expression of pro-inflamma-
tory genes and proteins. Many studies using xenografts 
have utilized uninfected controls (e.g. saline or medium). 
In porcine xenografts we noted that non-pathogenic E. 
coli K12 incited significant histopathologic changes that 
were statistically equivalent to those incited by C. jejuni 
relative to a saline control treatment (unpublished). In 
contrast, others have noted the pathogenic bacteria exac-
erbated the inflammatory response in xenografts relative 
to non-pathogenic bacterial controls [163, 176, 179]. The 
potential of the xenograft model as a comparative patho-
genicity model is currently uncertain.
Cannulation is a commonly applied method to allow 
researchers to temporally obtain samples from the gas-
tro-intestinal tract of animals. For this strategy, a fistula 
is established into the target region of the gastrointesti-
nal tract, and a cannula is inserted. Cannulation is com-
monly used to examine nutritional metrics in ruminants 
(e.g. ruminal, omasal, duodenal, jejunal, ileal cannula-
tion) [180–186], and less frequently to sample mucosa 
[187, 188]. The model has also been applied to monogas-
tric animals (small intestine, cecum, colon) including 
rabbits [189–192], dogs [193–196], pigs [197–199], and 
horses [200]. The cannulation method has the advantage 
of allowing researchers to temporally sample mucosa, 
digesta or both. The salient limits of this method are the 
complexity of the surgical procedure, the restriction of 
sampling to prescribed regions of the intestine, and the 
inability of treatments to be localized.
The establishment of intestinal ‘loops’ through surgery 
generates a model to study host-pathogen interactions 
in a prescribed manner. Intestinal loops have the added 
advantage of mimicking normal intestinal physiologic, 
immunologic, and histopathologic responses. Impor-
tantly, treatments can be localized to a specific region 
of the intestine. Furthermore, treatments can be repli-
cated within a single animal as part of the experimental 
design. Intestinal loop models can be divided into two 
basic types: recovery and non-recovery surgical proce-
dures. For the non-recovery type, loops are established in 
animals under general anesthesia. This involves ligating 
the small or large intestine to generate a compartment 
or compartments (±  flushing the intestinal segment to 
remove ingesta before generating the loops). Importantly, 
vascular and lymphatic functions are not disrupted by 
the procedure. While the animal is under anesthesia, 
treatments are introduced into the loop lumen via injec-
tion. After a defined period (typically not exceeding 24 h) 
the animal is euthanized, loops removed, and samples are 
collected and processed. Although non-recovery models 
are much more commonly used than recovery loop mod-
els, they are limited to short-term measures and this is 
the primary limitation of the model. Non-recovery loop 
models have been established in a variety of animals 
including rats, rabbits, sheep, and cattle [201–204]. In 
contrast the recovery loop model has the advantage of 
allowing researchers to measure treatment effects over a 
prolonged period (>6 months) [157]. For recovery mod-
els, the intestine is exposed in an animal under anesthe-
sia, and a section of intestine to generate the intestinal 
segment within which ‘loops’ will be established is identi-
fied and ligated [205]. The intestine is then cut, and the 
intestinal segment designated for loops is flushed with 
broad-spectrum antibiotics or saline. The non-intestinal 
segment side of the intestine is then rejoined to form a 
continuous and functioning intestinal tract. Each end 
of the intestinal segment is closed, the segment is parti-
tioned into ‘loops’, treatments are injected into the loops, 
and the abdominal cavity and muscle are closed. Animals 
are carefully monitored, and their recovery is uneventful. 
At the desired time, the animal is humanely euthanized, 
the compartmentalized intestinal segment is exposed, 
loops are removed, and samples are collected and pro-
cessed (Fig. 3). The primary disadvantages of the recovery 
model are its technical complexity, need of surgical infra-
structure, skill to successfully complete the surgical pro-
cedure, and requisite post-operative measures must be 
adhered including the administration of analgesics and 
antibiotics. The single window of opportunity to admin-
ister treatments (i.e. at the time of surgery) can also be 
a limitation of this model. Furthermore, samples of both 
the intestinal mucosa and luminal contents (e.g. sloughed 
mucosa within the loop lumen) can only be obtained at 
the termination of the project. For researchers studying 
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bacteria and inflammatory processes, the administra-
tion of antibiotics and analgesics can directly affect the 
treatment itself and alter immune function, thereby 
confounding results. As a result, a catheterized loop 
model was developed in which long-term catheters were 
inserted into the loops [205]. Notably, the establish-
ment of catheters in loops allowed for the introduction 
of multiple treatments over an extended interval, follow-
ing recovery from surgery and clearance of drugs admin-
istered during surgery and the post-operative period. 
Furthermore, observations from loop models that have 
been successfully established in sheep [205, 206] and pig 
(unpublished) have suggested that there is no effect on 
intestinal function following establishment of the loop 
[206]. A limitation of this model is that use of antibiotics 
does not eliminate microorganisms within the loops, and 
sloughed mucosa within the lumen of loops can interfere 
with the uniform distribution of administered treatments 
and sample collections.
Ethical, biosafety, and biosecurity considerations
All countries must adhere to standards for the ethical use 
of animals in research. In Canada, the Canadian Coun-
cil on Animal Care (CCAC) is the national peer-review 
organization responsible for setting, maintaining, and 
overseeing the implementation of standards for animal 
ethics and care in science (http://www.ccac.ca). Animal 
use is permissible only if the research promises to con-
tribute to the understanding of fundamental biologi-
cal principles, or to the development of knowledge that 
can reasonably be expected to benefit human beings or 
non-human animals. Animals should only be used if non-
animal alternatives do not exist. In the study of inflam-
mation, research must involve the use of animal models 
(i.e. to mimic the complex host–pathogen–microbi-
ome interaction). Animals used in inflammation based 
research must be maintained in a manner that provides 
for their physical comfort and psychological well-being, 
and expert opinion must attest to the potential value of 
studies with animals before research commences. A hall-
mark of inflammation is pain, and thus degrees of pain or 
distress are concomitant in studies of inflammation. The 
level of invasiveness and the procedures implemented to 
address this must be specified and evaluated in advance. 
Research studying inflammation commonly falls within 
invasiveness categories C (i.e. minor stress or pain of 
short duration) and D (i.e. moderate to severe distress 
or discomfort). However, in relatively rare instances, 
research may fall within invasiveness category E (i.e. 
severe pain near, at, or above the pain tolerance thresh-
old of unanesthetized conscious animals). As pain must 
be minimized both in intensity and duration, research 
that is categorized as invasiveness category E will not be 
approved without strong justification. The application of 
quantitative pain assessments is mandatory, and any ani-
mal observed to be experiencing severe and unrelenting 
pain or discomfort must be humanely euthanized (i.e. 
alternative endpoint). Similar guidelines are in place for 
the United States and the European Union (http://www.
ccac.ca/en_/resource-centre).
As research on inflammation commonly involves the 
use of biological incitants of enteritis (e.g. pathogens), 
research must also meet all requisite biosafety and bios-
ecurity standards to ensure safety. In this regard, all sci-
entific activities conducted within signatory countries 
that involve pathogens must adhere to United Nations 
conventions on biosafety and biosecurity. In Canada, 
biosafety and biosecurity is regulated by the Pub-
lic Health Agency of Canada, and the Canadian Food 
Inspection Agency under separate acts. The office of 
Laboratory Biosafety and Biosecurity specifies the physi-
cal and operational guidelines, and the evaluation and 
approval processes that must be met for research involv-
ing risk group 2, 3, and 4 organisms and toxins in labora-
tories and animal facilities, including the importation and 
distribution of animal pathogens (http://www.phac-aspc.
gc.ca/lab-bio/index-eng.php). The standards are specified 
within the Canadian Biosafety Standards and Guidelines 
(http://canadianbiosafetystandards.collaboration.gc.ca/
index-eng.php).
Choosing the appropriate animal model
Identifying the best animal model to study intestinal 
inflammation is an important consideration and requires 
a thorough understanding of the advantages and disad-
vantages of each model, as there are many factors to con-
sider. Animal models with comparable intestinal anatomy 
(monogastric vs. ruminant), function, and microbiome 
to human beings are typically the best models to exam-
ine intestinal inflammation; swine, rodents, zebrafish, 
and NHPs possess many traits in common with people. 
Moreover, animal models that can be genetically engi-
neered and have a similar genome to the human genome 
allow researchers to investigate specific genes related to 
intestinal disease. Most certainly, genetically modified 
mice have become instrumental to inflammation studies, 
due to their ability to display phenotypic traits definitive 
of specific gene manipulations. Animal husbandry is also 
an important factor to consider, as the cost of the facili-
ties and equipment can be prohibitive. Moreover, some 
animal species such as NHPs require enhanced training 
by animal care personnel and specialized veterinary care 
and service. The availability of biologic techniques and 
analytical tools necessary to study intestinal function 
and inflammation are also important factors to consider 
when choosing an appropriate animal model.
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Presently, there is no ‘perfect’ animal model that can 
address all the mechanisms involved in intestinal inflam-
mation. Each animal model has an array of advantages 
and disadvantages to its use and therefore a compre-
hensive study examining multiple aspects of intestinal 
inflammation requires the use of two or more animal 
models. For instance, using an invertebrate model to 
study mechanisms involved in innate immunity in con-
junction with a genetically engineered murine model 
could provide a broader understanding of the causes of 
intestinal inflammation with respect to both innate and 
adaptive immunity. Alternatively, a mouse model can 
be used to determine the immunologic mechanisms of 
pathogen challenge on the intestine, and these observa-
tions paired with the effects of the pathogen on intesti-
nal architecture and enterocyte function in the swine or 
NHP. Importantly, researchers must proactively consider 
the advantages and disadvantages of each model and 
determine the most suitable model(s) to address specific 
aspects of intestinal inflammation being investigated 
(Table 3).  
Methods to incite intestinal inflammation
The induction and subsequent progression of intestinal 
inflammation is a complex, multifactorial interaction 
between the host and its environment. In particular, the 
physiological status of the host plays an important role 
in the onset and severity of disease, and as such, prior 
use of products such as antibiotics can contribute to the 
establishment of pathogenic transient bacteria in acute 
inflammation [207]. Other factors such as age or genetic 
predisposition can also contribute to inflammatory dis-
ease development in chronic disease [18]. Although the 
onset of intestinal inflammation can occur spontaneously 
in various models [208, 209], the use of either chemi-
cal or biological incitants can be effective in inducing a 
rapidly developing and robust response. The array of 
chemicals available to induce intestinal inflammation 
permits one to choose between acute and chronic intes-
tinal responses, and some chemicals have the potential 
to incite both forms of inflammation. Similarly, various 
bacterial agents can induce both acute and chronic forms 
of intestinal inflammation. Chemical and biologi-
cal incitants of inflammation are necessary to simulate 
inflammation in appropriate models and often closely 
representative diseases may not be obtainable using a 
single model, necessitating the use of multiple models to 
accurately study the disease. Similar to choosing the best 
animal model to investigate specific aspects of intestinal 
inflammation, choosing the most effective chemicals and 
biological agents to incite inflammation must be carefully 
considered.
Chemical incitants
In animal models of inflammation, chemicals are often 
used as fast, economic and effective strategies to induce 
intestinal tissue injury. Animal models of colitis fre-
quently use either DSS or 2,4,6-trinitrobenzene sulfonic 
acid (TNBS) to initiate inflammation. Acetic acid, oxa-
zolone, and azoxymethane (AOM) have also been used, 
but to a lesser extent than DSS and TNBS (Table 4). The 
effectiveness of inducing tissue injury following treat-
ment with chemical agents varies and depends on the 
molecular weight, concentration, manufacturer, and 
batch of the chemical [210]. In addition, the species, gen-
der [56], and the genetic background of the animal model 
being challenged influences the degree of tissue injury 
[211, 212]. The method of administration also influences 
the induction and severity of disease, as some chemi-
cals work well to induce inflammation after ingestion 
[56], while others function best when applied directly to 
the site of infection, such as the rectal administration of 
haptenating agents [132]. Furthermore, microorganisms 
present in the intestine can interact with the chemical 
incitant and interfere with its ability to effectively incite 
tissue injury [213]. In general, chemical incitants induce 
tissue damage that can effectively represent clinical cases 
of intestinal inflammation.
Dextran sulphate sodium
Dextran sulphate sodium is used either independently 
or in conjunction with other chemicals to induce 
inflammation. By adjusting the concentration and dura-
tion of DSS treatment, the mechanisms involved in both 
acute and chronic inflammation can be studied. As an 
example, chronic inflammation in mice can be attained 
by administering DSS for 2 months in cycled rotations 
of 1 week of DSS treatment followed by 2 weeks of rest 
[211]. In contrast, DSS orally administered at a con-
centration of 1–5  % for approximately 1  week induces 
acute inflammation in the intestine [56, 214]. In general, 
DSS incites inflammation by disrupting the epithelial 
barrier, causing vascular and mucosal injury through 
the exposure of the lamina propria to luminal contents 
and bacterial antigens [215]. This exposure triggers the 
activation of inflammatory pathways resulting in an 
increased production of the inflammatory cytokines, 
TNF-α, IL-1β, IL-6, IL-10, IL-12 and IFN-γ [215]. Stud-
ies also show that in mice, expression of integrin-α M 
(ITGAM), integrin-α X (ITGAX), and IL-17 is increased 
following DSS treatment [216]. Long-term treatment 
with DSS increases IL-4 and IL-5 expression, suggest-
ing that DSS induced colitis is mediated by both Th1 
and Th2 immune mechanisms [215]. Furthermore, the 
factors involved in innate immunity are also affected 
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Table 3 Advantages and  disadvantages of  various animal models used to  study intestinal inflammation based on  the 
immune response elicited by biological and chemical incitants
Animal Model Type Immune 
mechanism
Incitant Advantage Disadvantage
C. elegans Invertebrate • Cost effective








• No adaptive 
component
• Limited applications
• No complex 
microbiome research
Drosophilasp. Invertebrate • Cost effective








• No adaptive 
component
• Limited applications
• No complex 
microbiome research
Zebrafish Invertebrate • Cost effective
• Adaptive immunity a 
factor at 3 weeks of 
age
• Minimal ethical 
considerations






• Small tissue size
• Different nutritional 
requirements
• Cost of germ-free 
facilities
• Cannot do diet or 
nutritional 
comparisons
Rodent Vertebrate • Easy genetic 
manipulation
• Microbiome studies 
possible
• Germ-free
• Gut-brain axis 
studies
• Use of adequate 
numbers for 
statistical relevance
• Small tissue sizein 
murine model
• Coprophagy limitation
• Difficult for invasive 
surgical techniques
• Cost and 
establishment of Level 




Vertebrate • Easy genetic 
manipulation
• Microbiome studies 
possible
• Intestinal loop 
models applicable
• Cost and 
establishment of Level 
2 handling facilities
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Table 3 continued
Swine Vertebrate • Easy genetic 
manipulation
• Microbiome studies 
possible





• Cost and 
establishment of Level 
2/ germ -free handling 
facilities
• Overwhelming amount 
of tissue
• Husbandry and 
personnel training
• Slight variation in 
immune cells and large 
intestine orientation
Ruminant Vertebrate • Intestinal loop 
models applicable
• Beneficial for enteric
pathogen studies i.e. 
O157:H7
• Level 2 handling 
facilities
• Overwhelming amount 
of tissue
• Husbandry and 
personnel training
• Intestine not well 
studied
• Microbial 
fermentation occurs in 




Vertebrate • Anatomically and 
genetically similar to 
humans
• Gut-brain axis 
studies 
• Microbiome studies 
possible
• Human disease 
present with similar 
sequelae to human
• Ethical considerations
• Level 2 handling 
facilities
• Disease transmission
• Husbandry and 
personnel training








 Adaptive immune response with associated mechanism;  Innate response with associated immune mechanism;  




Table 4 Chemicals used to incite acute and chronic intestinal inflammation
Chemical Effect Disease-like symptoms
Dextran sulphate sodium (DSS) Extensive basal crypt and epithelial cell damage with 
long-term administration, increase in IFN-γ, IL-6, 
TNF-α, IL-4 and IL-5; Th1 and Th2 mediated immune 
response [59]
Acute mucosal and vascular injury in low concentra-
tions, develops in UC-like symptoms
Trinitrobenzene sulfonic acid (TNBS) Th1 mediated immune response, ↑IL-12, TNF-α and 
IFN-γ [212]
Initial effects are acute in nature, develops into CD-like 
symptoms
Oxazolone Th2 mediated immune response, ↑IL-4, IL-5 and IL-13 
[211]
Initial effects are acute in nature, develops into UC-like 
symptoms
Azoxymethane (AOM) Used in conjunction with DSS, tumour inducing, can 
lead to increased IL-21, IL-17A and IL-6; Th1/Th17 
mediated immune response [298]
Colorectal cancer-like symptoms when used in conjunc-
tion with DSS
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by DSS treatment, as treatment with DSS changes 
the expression of MyD88, TLR4 and TLR9, and small 
changes in these mediators of innate immunity contrib-
ute to epithelial cell damage and subsequent intestinal 
inflammation [56].
Many factors affect the propensity of DSS to induce 
inflammation in different animal models. The bacte-
rial population within the colon is a critical factor in 
modulating the severity of the tissue response caused 
by DSS treatment. This is observed in DSS treated 
germ-free mice, which develop severe colitis upon treat-
ment with 1  % DSS, whereas conventional mice with 
an intestinal microflora showed only minor intestinal 
crypt damage and a relatively non-severe colitis with 
the same treatment [213]. The ability of DSS treatment 
to induce intestinal inflammation is also affected by the 
genetic background of the animal species. For instance, 
C3H/HeJ mice are sensitive to DSS treatment, whereas 
C57BL/6 mice are relatively resistant [56]. For instance, 
C3H/HeJ mice treated with DSS have greater occurrence 
of bloody diarrhea, epithelial ulceration, inflammation, 
and weight loss as compared to C57BL/6 mice [56, 217]. 
In addition to mice, pigs have been used to examine 
DSS induced intestinal inflammation. Young et al. [218] 
observed increased expression of TNF-α, IL-6, IFN-γ, 
and IL-17A in pigs administered DSS, an observation 
that is similar to clinical patients suffering from active 
IBD. Other studies in pigs report increased lymphocyte 
infiltration in mucosal tissue as well as mucosal erosion 
and crypt destruction following DSS treatment, and that 
these tissue changes are similar to the intestinal lesions 
often present in people afflicted with IBD [219].
Although DSS is an effective inducer of intestinal 
inflammation, there are potential drawbacks to its use in 
animal models. Most notably, there can often be signifi-
cant inter-animal variability in the severity of tissue injury. 
In many cases, marked inconsistency in the amount of 
mucosal damage and in particular epithelial cell necrosis is 
observed [56, 210]. Furthermore, the molecular composi-
tion and purity of the chemical product can vary between 
the product batches and chemical supplier, potentially 
leading to inaccurate concentrations and volumes of DSS 
administered to the test animals [211]. Although the level 
of tissue injury can vary between treatment groups with 
DSS, it is still considered a model chemical incitant of 
intestinal injury and is commonly used to stimulate UC-
like lesions in various animal models.
Azoxymethane
The severity of inflammation can be enhanced by admin-
istering chemical incitants of inflammation in combina-
tion with another chemical inducer of inflammation. 
Long-term administration of DSS with AOM induces 
chronic intestinal inflammation that often progresses 
to CRC [220]. Notably, the intestinal lesions induced by 
DSS with AOM treatment are consistent with intestinal 
changes manifested by patients with UC [59]. Treatment 
with these two chemicals alters tissue cytokine profiles 
in mice resulting in increased expression of IL-4 and 
IFN-γ, parallel to expression in patients with UC [59]. 
Furthermore, the administration of AOM with DSS is 
necessary to exacerbate the effects of DSS to induce the 
development of colorectal cancer [221], an event that 
can on occasion occur in people with UC [2]. Thus, the 
combined use of both chemicals is ideal for investigating 
both inflammatory diseases of the intestine, as well as the 
pathophysiology of colorectal neoplasia.
The administration of AOM alone has also been used to 
study mechanisms that induce cancer in the distal colon 
[222]. Proposed mechanisms for the induction of inflamma-
tion and tumour formation by AOM include the upregula-
tion of cyclooxygenases leading to the enhanced production 
of prostaglandin E2 [220], and the induction of pro-muta-
genic epithelial changes caused by the O6 methylation of 
guanine to induce tumour formation [223]. Several other 
metabolic pathways are also affected by AOM metabolism, 
including the k-ras regulated MAPK intracellular signalling 
pathway, the cellular adhesion related B-catenin pathway, 
and the epithelial cell apoptotic TGF-β pathway [222].
Trinitrobenzene sulfonic acid
Trinitrobenzene sulfonic acid is primarily used to estab-
lish acute intestinal inflammation in animal models, 
but can also be employed to induce chronic inflamma-
tion in rodents [79, 224], pigs [225], rabbits [56], guinea 
pigs [52], and NHPs [226]. To become chemically active, 
TNBS needs to be solubilized in ethanol, and this TNBS-
ethanol mixture induces intestinal inflammation by 
altering host proteins through the formation of covalent 
bonds with trinitrophenyl haptens of TNBS [132]. This 
process stimulates an immune-mediated inflammatory 
response. The TNBS-ethanol mixture produces ‘hapten 
modified self-antigens’ that are recognized by the host 
immune system and contribute to acute intestinal inflam-
mation [132]. Moreover, ethanol also acts as an irritant 
that contributes to the damage of the epithelial barrier 
[214]. Treatment with TNBS-ethanol can also produce 
intestinal lesions representative of those present in indi-
viduals with IBD [72]. It has also been shown that rec-
tal administration of TNBS in 40–50  % ethanol leads 
to colon shortening, intestinal hemorrhage, epithelial 
necrosis causing crypt architecture destruction, and 
transmural inflammation accompanied by an elevated 
Th1 immune response within the colon [214, 227].
Trinitrobenzene sulfonic acid can be used as an incit-
ant of both acute and chronic inflammation. In acute 
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inflammation of mice, the primary immune response 
observed follows a pro-inflammatory Th1 response, 
increasing the expression of IL-12, IFN-γ and TNF-α [214, 
228]. An increase in IL-23 production indicates the initia-
tion of chronic colitis in BALB/c mice, and as colitis pro-
gresses, the cytokine profile changes to a Th17 dominant 
response, evident by increased IL-17 and IL-25 expres-
sion, before ultimately switching to an IL-13 dominant 
immune response [228]. Research also suggests that a 
T-cell deficient mouse exhibit chronic enteric inflamma-
tion in the presence of IL-23, making this cytokine a deter-
minative marker for chronic enteritis [229]. Importantly, 
these observations are aligned with cytokine profiles in 
CD patients as these individuals display elevated levels of 
IL-17, IL-22 and IL-23 [230, 231]. Rats supplemented with 
TNBS often lose weight, present with bloody diarrhea, and 
exhibit marked mucosal and transmural intestinal inflam-
mation, similarly to people with IBD [232].
Although intestinal inflammation has been established 
in rodents, swine, and NHPs using TNBS as the chemical 
incitant [52, 56], evidence indicates that mice are the best 
models for investigating TNBS-ethanol induced colitis 
[233]. When selecting the most appropriate mouse strain 
to examine TNBS induced tissue injury, the genetic back-
ground and phenotypic profile of the mouse are important 
factors to consider. As examples, C57BL/6 and DBA/2 
strains are relatively resistant to treatment with TNBS, 
whereas SJL/J, C3HeJ and BALB/c mice produce signifi-
cant tissue injury following exposure to TNBS [132].
Oxazolone
Oxazolone is an alternative chemical agent that can be 
used to produce ‘hapten-like proteins’ in the host intes-
tine to induce acute intestinal inflammation [234]. Its use 
results in intestinal lesions associated with a predominant 
Th2 immune response. The tissue lesions manifested in 
mice following exposure to oxazolone are similar to UC-
like lesions in people, with most lesions causing mucosal 
ulceration, submucosal edema, and tissue hemorrhag-
ing [234]. In mice, oxazolone administration has been 
attributed to body weight loss, diarrhea, ulcers, and loss 
of epithelial cells in the large intestine [211, 234]. One of 
the advantages of using oxazolone to induce tissue injury 
is the rapid progression of tissue architecture alteration 
in comparison to other chemical agents [234]. Indeed, 
the relatively fast induction of tissue damage makes oxa-
zolone an ideal candidate to study UC-like disease in 
mice, as histological evidence shows an increase in IL-4, 
IL-5, and IL-13, cytokines that are indicative of a Th2 
immune response [211]. Similarly to TNBS and DSS , the 
choice of mouse strain will influence the effects of oxa-
zolone treatment on tissues. As an example, oxazolone 
treated BALB/c mice show increased tissue injury when 
compared to C57BL/6 mice under the same treatment 
[234]. Although oxazolone is an effective inducer of acute 
inflammation, its effectiveness to induce chronic inflam-
mation remains undetermined, as few investigations 
have examined its potential to cause long-term intestinal 
inflammation [234, 235].
Chemical incitation of intestinal injury
Chemical incitants induce tissue injury by initially dis-
rupting the epithelial barrier, exposing the lamina propria 
to intestinal contents, and stimulating pro-inflammatory 
cytokine activity. Dextran sulphate sodium, AOM, TNBS, 
and oxazolone cause tissue injury within the intestine, 
and have been especially effective in inducing injury 
within the distal colon [211]. Each incitant has the ability 
to induce distinct tissue lesions accompanied by specific 
helper T-cell cytokine cascades during inflammation. 
Individually, these chemicals are all effective inducers of 
disease-specific injury. For instance, DSS is very useful as 
a chemical model for UC-like intestinal injury [236, 237], 
whereas oxazolone provides the benefit of quick injury 
development and rapid tissue damage compared to the 
other three chemical agents [228]. If developing chronic 
inflammation in the intestine is the main focus of study, 
then TNBS and DSS are the most appropriate chemicals 
to use. In summary, TNBS, DSS, AOM, and oxazolone 
are all useful chemicals to induce intestinal inflamma-
tion in animal models, and the best chemical agents 
to employ depends on the specific aspect of intestinal 
inflammation under investigation. Chemical incitants 
are the most common agents used to induce intestinal 
injury and inflammation, and are often considered the 
best methods to study the immune response associated 
in intestinal disease. Chemicals agents are an inexpensive 
[47], quick, and effective method to cause inflammation, 
and these agents are valuable tools in the armamentar-
ium for investigating the pathophysiology of intestinal 
inflammation.
Biological incitants
As an alternative to using chemical incitants, biological 
incitants have also been used to study common intesti-
nal inflammatory diseases. Biological incitants can be 
bacterial, viral, protozoal, or helminthic, and can be used 
to induce both acute and chronic inflammation. Herein 
we review the most commonly used biological agents to 
induce intestinal inflammation in animal models.
Bacteria
The host intestinal tract contains a diverse community of 
bacteria totalling 1013–1014 bacterial cells [238], with spe-
cies most often belonging to the Bacteroidetes, Firmicutes, 
Actinobacteria, Spirochetes, and Proteobacteria phyla 
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[239, 240]. Homeostatic interactions between the host 
and the resident microbiome occur in the intestine , and 
changes in bacterial species abundance can potentially 
lead to intestinal inflammation [240]. It has been well 
investigated that the commensal bacteria are important 
in maintaining a healthy intestine by preventing the over-
growth of pathogenic microorganisms, and assisting in 
regulating and maintaining a quiescent intestinal immune 
system [41]. An uncontrolled immune response to com-
mensal bacteria can lead to intestinal injury, and reports 
indicate that the development of aberrant immune 
responses can occur from increased exposure to the com-
mensal bacteria [25, 239]. Moreover, modifications to the 
community structure of the intestinal microbiome can 
incite disease, often by the uncoordinated expression of 
pro-inflammatory cytokine profiles in concert with the 
simultaneous loss of anti-inflammatory signalling [239, 
241]. A well characterized model for studying acute 
inflammation involves using C. rodentium, a attaching 
and effacing bacterium that colonizes the cecum and large 
intestine of mice [242–244]. Infection with C. rodentium 
in susceptible mice is relatively short-lived, and because 
peak infection is observed around day 14 with clearance 
by day 28, this bacterium is more suitable for studying 
acute mechanisms of inflammation [241]. Although C. 
rodentium lesions model acute inflammation, its infec-
tion produces both ulcerative and proliferative intestinal 
lesions that represent those identified in patients with 
UC, including dysplastic changes associated with intesti-
nal carcinomas [245]. Importantly, mice have been used 
to study the progression of tissue injury, and to identify 
the temporal relationship in cytokine expression by four 
different T helper CD4 T-cells subtypes (Th1, Th17, Th2, 
and Treg) [246]. As infection  progresses, the cytokine 
profile changes to a Th17 dominant response, evident by 
the increased expression of pro-inflammatory cytokines 
IL-17 and IL-22. Although 21 days is not usually consid-
ered chronic, this trend was noted in mice challenged 
with C. rodentium, and initiated with a prominent Th1 
immune response that slowly switched to a Th17 domi-
nant response near the clearance of infection around day 
21 [246].
Citrobacter rodentium also serves as an alternative 
mouse model to study the virulence mechanisms related 
to EHEC and Enteropathogenic E. coli (EPEC) infection 
that use attaching and effacing lesions to attach to and 
remodel the intestinal epithelium for bacterial entry and 
damage [247]. A prominent EHEC serotype is O157:H7; 
this serotype of E. coli is naturally found in cattle and 
other ruminants, and has been responsible for numer-
ous foodborne related illnesses, and hospitalizations and 
deaths around the world [248]. Pathogenesis is associated 
with the presence of the locus of enterocyte effacement 
(LEE) pathogenicity island, which is responsible for the 
production of the Type 3 secretion system, Shiga tox-
ins, Tir, intimin, and enterohemolysin [248]. Citrobacter 
rodentium is also a LEE positive organism and utilizes 
attaching and effacing lesions to facilitate infection; how-
ever, it does not produce a Shiga toxin, meaning the tis-
sue damage observed is not hemorrhagic , but displayed 
as transmissive colonic hyperplasia allowing the passage 
of immune cells into the lumen of the colon [247]. A 
number of small and large animal models have been used 
to study EHEC and EPEC colonization and pathogenesis 
including mice, rats, rabbits, pigs, cows, dogs, baboons, 
and macaques [249]. No single animal model can mani-
fest lesions that are representative of EHEC-associated 
disease observed in people, as such using multiple ani-
mal models is a better strategy to understand intestinal 
inflammation in people caused by EHEC.
Helicobacter pylori are gram negative bacteria associ-
ated with the development of gastric ulcers in people. 
Helicobacter spp. can occupy the gastric epithelium, 
the intestine, and the liver in afflicted individuals [250], 
and have been known to colonize a variety of animals 
including pigs and opossums, as well as non-mammals 
such as tortoises and birds [251]. Research groups are 
now investigating a link between H. pylori infection and 
IBD [252–254]. Urease positive Helicobacter spp. found 
in the stomach and proximal small intestine of hosts, 
have been suggested to cause damage to the ileum and 
colonic mucosa with cytotoxins released in the presence 
of urease, and its these products that appear to contrib-
ute to the development of UC and CD-like symptoms in 
humans [250].
The genetics of the animal model used has a significant 
effect on the pathophysiology of bacterial induced intes-
tinal injury. For example, C57BL/6 mice will develop a 
predominant Th1 mediated cellular response resulting 
in extensive epithelial cell injury and cell proliferation 
when infected with small numbers of H. pylori and H. 
felis [255]. In contrast, BALB/c mice will develop a Th2 
mediated cellular response with minimal intestinal injury 
following challenge with large numbers of H. pylori and 
H. felis [255]. Studies show that non-H. pylori helico-
bacters cause IBD-like conditions in animal models, and 
paradoxically, research shows H. pylori can reduce the 
development of IBD in people with repeated H. pylori 
infections [256]. In such individuals, increased levels of 
Foxp3 and reduced intestinal inflammation have often 
been observed [256, 257]. Experimental colitis leading to 
cancer has also been induced using H. bilis and H. hepat-
icus in mice 4–6 weeks post-infection, and can contribute 
to the development of chronic intestinal inflammation 
in mice [258, 259]. Helicobacter hepaticus is often iso-
lated in the livers and colons of infected mice [260], and 
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induces hepatitis, enteritis, typhlocolitis, and IBD-like 
tissue injury in many genetically modified mouse models 
[64, 261]. Helicobacter hepaticus-induced enteric inflam-
mation has been observed in A/JCr, BALB/cAnNCr, 
SJL/NCr, C3H/HeNCr, Rag−/−, IL10−/−, and SCID mice 
reconstituted with CD45RBhigh T-cells [262]. Challenge 
studies with H. hepaticus in these models will develop 
CD-like lesions and are used to investigate mechanisms 
involved in the development of IBD in people [263]. As 
more information on the mechanisms involved in tis-
sue injury caused by H. hepaticus are known, the use of 
this agent to study intestinal inflammation is expected to 
increase.
Investigations show S. enterica serovar Typhimurium 
can be used as a chronic model of intestinal inflamma-
tion in  mice. This bacterium invades mucosa 27  weeks 
after infection and breaches the epithelium leading to the 
development of tissue injury in the deeper layers of the 
intestine [264]. A breach in the epithelium can also act 
as a conduit for prolonged mucosal translocation of the 
bacterium. Salmonella enterica serovar Typhimurium is 
used extensively in research as a non-typhoidal Salmo-
nella infection  model, which most often causes a non-
septicemic form of enterocolitis in cattle and humans 
[207]. Mice are relatively resistant to developing typhoid-
like lesions following exposure to S. enterica serovar 
Typhimurium [207], however, the severity of the lesions 
can be markedly enhanced by antibody treatment. This 
phenomenon suggests that disruptions in the intestinal 
microbiome can influence the effects of S. enterica sero-
var Typhimurium in the murine and bovine intestine [72, 
156]. Further, pre-treatment with streptomycin in mice 
produces intestinal damage that includes epithelial crypt 
loss, mucosal erosion, and neutrophil infiltration that are 
similar to lesions observed in people with UC [72, 207].
Choosing a proper animal model is an important 
consideration for studying   salmonellosis. As exam-
ples, exposing LTβR knockout mice to S. enterica sero-
var Typhimurium produces acute and marked intestinal 
lesions comparable to human IBD lesions. These lesions 
can be accompanied by edema, disruption of the villus 
architecture, goblet cell depletion, and increased ICAM-1 
expression [207]. Murine lesions also show striking simi-
larities to S. enterica serovar Typhimurium infection 
in calves, NHPs, and people [207]. Similarly, iNOS−/−, 
IL-10−/−, and CD40L−/− mice challenged with S. enterica 
serovar Typhimurium also develop enterocolitis [265]. 
Finally, Salmonella spp. are intracellular pathogens, and 
clearance of disease requires a coordinated Th1 and Th17 
immune response [266]. As such, mice and NHP mod-
els have been used to investigate the expression of Th1 
cytokines TNF-α, IFN-γ, IL-12, IL-15, and IL-18 [267], as 
well as the Th17 cytokine IL-17 in association with intes-
tinal inflammation [268].
Mycobacterium avium subspecies paratuberculosis is 
the leading cause of Johne’s disease in cattle, and causes 
weight loss, diarrhea, and mortality in ruminants [153]. 
Indeed, intestinal changes in ruminants with Johne’s dis-
ease are similar to intestinal changes present in people 
with CD [154]. As well, Map has frequently been found 
in the environment of infected herds. Individuals with 
CD who have been in close contact with or consumed 
milk from infected cattle also present with Map [153, 
269]. Research suggests Map is a useful associative model 
to investigate CD in people [153, 269, 270]. Experiments 
in mice demonstrate  that Map can induce intestinal 
lesions following exposure that are highly similar to those 
changes seen in individuals with CD [271]. As examples, 
beige/SCID mice treated with Map have breaches in the 
small intestine mucosal barrier, and marked thickening 
of the intestinal lamina propria associated with the infil-
tration of bacteria laden epithelioid-macrophages [270]. 
Infections with Map have also been identified in captive 
rhesus macaques with chronic diarrhea and intestinal 
injury similar to lesions that are present in ruminants 
[131, 272]. Collectively, these observations suggest Map 
is a good associative model used to study intestinal dis-
ease in people.
The above information suggests that C. rodentium, 
Helicobacter spp., S. enterica serovar Typhimurium, 
and Map can be used as bacterial agents to induce and 
maintain acute to chronic intestinal inflammation in dif-
ferent animal models. Importantly, these models appear 
to represent intestinal changes observed in people with 
intestinal inflammatory disease. Similarly to other incit-
ants of inflammation, these bacteria can be employed not 
only as primary inducers of inflammation, but also used 
in concert with other agents (i.e. chemical irritants), pro-
viding an effective ‘challenge regime’ to study the mecha-
nisms involved in induction and progression of intestinal 
inflammation.
Helminths
Helminths (i.e. flukes, tapeworms, and roundworms) 
can cause extensive intestinal inflammation and injury in 
people and are primarily used to investigate Th2 medi-
ated inflammation in the intestine [273]. Parasites pri-
marily induce the expression of Th2 (IL-4, IL-5, IL-13) 
and Treg (IL-10, TGF-β) cytokine profiles in conjunction 
with eosinophil-associated tissue inflammation [274]. 
Nematodes (i.e. roundworms) are the most commonly 
used helminth model to study intestinal disease, and 
Trichuris muris is the most frequently used nematode 
to incite intestinal inflammation in rodents [273]. The T. 
muris murine model induces an acute immune response 
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characterized by the loss of barrier function in the cecum 
and proximal colon [275]. In addition, T. muris elic-
its a strong Th2 T-cell response following exposure to 
large amounts of parasite eggs, and this agent can pro-
duce intestinal lesions similar to those observed in mice 
treated with oxazolone [273]. In mouse models such as 
C57BL/6 and BALB/c mice, infection results in an upreg-
ulation of Th2 cells that secrete IL-4, IL-5, and IL-13, and 
increase epithelial cell turnover and permeability [273, 
276]. Interestingly, although helminths primarily pro-
duce a Th2 immune response in the mouse intestine, T. 
muris induces a Th1 mediated response associated with 
increased levels of IL-12, IL-18, and IFN-γ in AKR/J mice 
[276]. This event, however, fails to clear the parasite and 
facilitates the development of a chronic intestinal infec-
tion [273], making T. muris infected AKR/J mice a useful 
chronic inflammatory incitant model.
The severity of inflammation observed after exposure 
to helminths varies depending on the genetic background 
of the animal model. The progression of tissue injury and 
the type of immune response developed can be affected 
by the number of eggs administered. For example, T. 
muris treated mice develop a strong Th2 response to high 
loads of parasite eggs (>150 eggs). In contrast, AKR/J 
mice develop a significant Th1 response following treat-
ment with low numbers of parasite eggs (<15 eggs) over 
a 36 day period [277]. Importantly, T. muris infection in 
AKR/J mice is associated with enterocyte hyperplasia, 
and decreased mucin secretion [278, 279], observations 
that are also evident in patients with IBD [280]. In con-
clusion, the T. muris model is a proficient model to study 
either early Th2 acute inflammatory responses (C57BL/6 
and BALB/c mice) or Th1 induced chronic intestinal 
inflammation in the AKR/J mouse model.
Protozoa
Toxoplasma gondii has also been used in mouse models 
to promote intestinal inflammation. Toxoplasma gondii 
infection in susceptible mouse strains is able to produce a 
robust Th1 associated pro-inflammatory response in the 
small intestine [281]. This organism has three pathogenic 
strains, and of these, strain 2 is considered particularly 
pathogenic in people, and is able to elicit a strong Th1 
cytokine response resulting in increased IL-12 and IFN-γ 
expression [281]. Other studies have shown that T. gondii 
infection can induce the production of IL-22, an effector 
cytokine associated with activated Th17 cells [282]. Fur-
thermore, administration of low numbers of protozoan 
cysts (20–50) to C57BL/6 and SCID mice incited pro-
longed episodes of enteritis [282]. In C57BL/6 mice the 
chronic intestinal lesions were characterized by promi-
nent infiltrates of macrophages into the lamina propria, 
contributing to ileal inflammation and mucosal necrosis, 
an observation similar to patients with CD [283]. This 
suggests that T. gondii is a useful agent to study chronic 
intestinal inflammation in mice.
Viruses
Presently, there are few studies that conclusively demon-
strate a direct link between viral infections and intestinal 
inflammation. Most of these studies show only an obser-
vational relationship between the induction of intestinal 
inflammation by viruses and the onset of IBS or IBD in 
people [284]. Most studies examined coincidental associ-
ations between the presence of IBD in patients, the exist-
ence of viral pathogens and their remnants (i.e. genomic 
DNA) within the intestine [285], and the ability of viruses 
to exacerbate pre-existing disease [286]. One example is 
the link between early onset childhood measles and the 
subsequent development of intestinal disease in which 
infants with previous history of measles-associated-
pneumonia, diarrhea, and weight loss developed CD or 
UC later in life [287]. Another example is the relationship 
between paramyxovirus and Epstein–Barr virus and the 
development of IBD, where either remnants of the virus 
or lymphocytes infected with viral particles, respectively, 
are present in the intestine [24, 288]. Although these 
studies do not conclusively prove viral infections induced 
intestinal inflammation in healthy people, it is possible 
that viruses can readily affect immunosuppressed indi-
viduals. Studies in immunocompromised NHP animal 
models and immunocompromised people with UC and 
CD demonstrate that intestinal inflammation and injury 
can be both induced [289] and exacerbated [24, 290, 291] 
following exposure to viral pathogens. Mouse models 
have also been used to facilitate acute colitis using cyto-
megalovirus to exacerbate DSS-induced colitis [292]. 
From the information described, it appears that a causal 
association between viral infections and the induction 
of intestinal inflammation in immunocompetent indi-
viduals remains undetermined. It suggests, however, that 
immunosuppressed individuals and animal models are 
more susceptible to the development of virally-induced 
intestinal inflammation. In as such, viruses may only be 
an effective tool to investigate the mechanisms involved 
in intestinal inflammation in immunodeficient animal 
models.
Comparison of biological incitants
Biological incitants offer the advantage of being able to 
study both acute and chronic inflammation using agents 
that naturally cause inflammation in human and non-
human animal tissues. A plethora of biological incit-
ants exist that can be applied to examine inflammation; 
most of these agents have been investigated and are 
known to cause infection in the intestine of mammals. 
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Bacterial incitants such as Salmonella spp. and Helico-
bacter spp. have been used to mimic intestinal infection 
in animal models, and much is known about their mode 
of infection through information attained from human 
infections. Most of these incitants are best used when 
examining the effects of acute inflammation, however 
helminth and protozoan models are better suited for 
chronic inflammatory studies. Long-term enteritis can be 
induced in susceptible murine models using low levels of 
T. gondii eggs [282], whereas T. muris has the ability to 
facilitate Th1 mediated chronic inflammation in AKR/J 
mice [277]. The use of other agents can further enhance 
the effect of T. gondii on intestinal injury. For instance, 
Stoicov et  al. [293] demonstrated that co-infection with 
H. felis and T. gondii induce significant mucosal damage 
and chronic inflammation in BALB/c  mice. The result-
ing lesions are associated with a prominent Th1 immune 
response and muted Th2 immune response that con-
sequently develops into long-term injury to the upper 
gastrointestinal tract mucosa [293]. Although Map and 
viral incitants have not been definitively associated with 
the onset of intestinal inflammation, the ability of these 
microorganisms to be either co-isolated with afflicted 
individuals or to exacerbate infection suggests a func-
tional role for Map and viral agents in IBD immunity [24, 
153, 290]. As the human intestine is occupied by many 
bacterial species that are critical to intestinal function 
and homeostasis, the use of models that can replicate this 
diverse and complex relationship yet allow alterations 
(e.g. dysbioses) in this community are best for studying 
intestinal inflammatory diseases. Utilizing bacterial spe-
cies that cause damage in both human and non-human 
animal intestines allows for comparable experimental 
conditions that can help in understanding dysbioses in 
relation to inflammatory bowel diseases.
Conclusions
As the prevalence of intestinal inflammatory diseases 
continues to increase, it is becoming increasingly impor-
tant to elucidate causes and possible mitigation strate-
gies. Intestinal disease can arise from a variety of factors, 
and the complex interactions between the host and the 
intestinal microbiome make determining the mecha-
nisms involved in the induction and progression of dis-
ease challenging. Currently, a variety of animal models 
can be used to study the processes involved in intestinal 
inflammation, however, rodent models and in particular 
genetically engineered mice are the primary models used 
to study acute and chronic intestinal inflammation. The 
ability to modify the genetic background in mice allows 
specific questions to be addressed, and importantly, the 
information from mice can be compared to other ani-
mal models and extrapolated to human beings. The 
generation of spontaneous, long-term intestinal inflam-
mation can be a lengthy process, so the use of chemical 
and bacterial incitants to expedite the process is often 
necessary. Each incitant of inflammation has the inher-
ent ability to develop specific manifestations of tissue 
injury as well as corresponding immune responses within 
various animal models, and as such, determining which 
agent (chemical vs. biological) to use requires careful 
consideration. Furthermore, the association between the 
intestinal microbiome and the host adds another level 
of complexity to the pathobiology of intestinal inflam-
mation. The use of animal models, appropriate chemi-
cal and/or biological incitants, and eventually applicable 
analytical tools are all required to study inflammation 
within the intestine. Together, these components facili-
tate our understanding into the mechanisms involved 
in the pathophysiology of intestinal disease and poten-
tially set the foundation for the development of mitiga-
tion strategies that can treat intestinal inflammation in 
people.
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